The PROTAC molecule itself contains three distinct portions: a ligand for binding to the target protein, a ligand for binding to an E3 ligase, and a linker joining these two ligands.

PROTACs (proteolysis-targeting chimaeras) are bifunctional molecules that bring a target protein into spatial proximity with an E3 ubiquitin ligase to trigger target ubiquitination and subsequent proteasomal degradation. Effective redirection of ligase poly-ubiquitination activity toward a new substrate protein requires formation of a ligase:PROTAC:target ternary complex, an intermediate species that is crucial to the cellular activity of degrader molecules. A characteristic feature of PROTACs mode of action is their sub-stoichiometric catalytic activity that alleviates the requirement for target engagement and occupancy of traditional inhibitors. New PROTAC molecules designed guided by the crystal structure show exquisite selectivity for inducing cellular depletion of Brd4 over its BET family members Brd2 and Brd3.

PROTAC Related Products (18):

Cat. No. Product Name Effect Purity
  • HY-100972
    ARV-771 99.44%
    ARV-771 is a potent bromodomain and extra-terminal (BET) proteins degrader based on PROTAC technology with Kd values of 4.7, 7.6, 7.6 nM against BRD2, BRD3 and BRD4, respectively.
  • HY-16954
    ARV-825 99.37%
    ARV-825 is a BRD4 Inhibitor based on PROTAC technology. ARV-825 binds to BD1 and BD2 of BRD4 with Kds of 90 and 28 nM, respectively.
  • HY-101838
    dBET1 99.24%
    dBET1 is a potent BRD4 protein degrader based on PROTAC technology with an EC50 of 430 nM.
  • HY-101763A
    Protein degrader 1 hydrochloride 98.63%
    Protein degrader 1 hydrochloride is used in the synthesis of HaloPROTACs.
  • HY-107443
    Target Protein-binding moiety 4
    Target Protein-binding moiety 4 is a BRD4(1) inhibitor with an IC50 of 7.9 μM.
  • HY-101519
    BETd-260 is a potent BET degrader based on PROTAC technology, with an IC50 of 30 pM against BRD4 protein in RS4;11 leukemia cell line.
  • HY-112495
    HaloPROTAC 2 98.10%
    HaloPROTAC 2, a chloroalkane-containing PROTAC, induces degradation of HaloTag fusion proteins.
  • HY-107445
    Target Protein-binding moiety 6
    Target Protein-binding moiety 6 is a compound that binds to BRD9, and used for inhibiting BRD9 activity.
  • HY-103628
    PROTAC 6 99.04%
    PROTAC 6 is a selective CDK9 degrader.
  • HY-107425
    MZ 1 99.35%
    MZ 1 is a BRD4 protein degrader based on PROTAC technology.
  • HY-111433
    BRD4 degrader AT1
    BRD4 degrader AT1 is a highly selective Brd4 degrader based on PROTAC technology, with a Kd of 44 nM for Brd4BD2 in cells.
  • HY-107452
    Target Protein-binding moiety 13
    Target Protein-binding moiety 13 is a synthetic ligand for FKBP (SLF), which is used in the synthesis of PROTACs.
  • HY-103633
    PROTAC 11
    PROTAC 11 is a potent BET degrader based on PROTAC, decreasing BRD2, BRD3, and BRD4 protein levels at low concentration.
  • HY-107447
    Target Protein-binding moiety 8
    Target Protein-binding moiety 8 is a compound binding to BCR-ABL, and used for inhibiting BCR-ABL activity.
  • HY-112098
    PROTAC 15
    PROTAC 15 comprises an ubiquitin E3 ligase binding group, a linker and a protein binding group. PROTAC 15 extracts from patent WO2017201449A1, compound P1. PROTAC 15 is an estrogen receptor-alpha (ERα) degrader.
  • HY-112376
    MZP-54 98.05%
    MZP-54 is a selective degrader of BRD3/4 based on PROTAC technology, with a Kd of 4 nM for Brd4BD2.
  • HY-112375
    AT6 is a PROTAC AT1 analogue, which is a highly selective bromodomain (Brd4) degrader.
  • HY-112377
    MZP-55 is a selective degrader of BRD3/4 based on PROTAC technology, with a Kd of 8 nM for Brd4BD2.
Isoform Specific Products

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.